These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8269667)

  • 1. Myocardial infarction, thrombolytic therapy, and economics.
    Shander D
    Clin Cardiol; 1993 Nov; 16(11):845. PubMed ID: 8269667
    [No Abstract]   [Full Text] [Related]  

  • 2. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Thrombolytic therapy].
    de Gaetano G; Donati MB; Gensini GF; Restagno C
    Recenti Prog Med; 1993 Sep; 84(9):581-5. PubMed ID: 8210621
    [No Abstract]   [Full Text] [Related]  

  • 4. Thrombolytic therapy for acute myocardial infarction.
    Clem JR
    S D J Med; 1994 Jan; 47(1):27-8. PubMed ID: 8122094
    [No Abstract]   [Full Text] [Related]  

  • 5. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
    Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
    Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of tissue plasminogen activator.
    Lee TH
    N Engl J Med; 1995 May; 332(21):1443-4. PubMed ID: 7723804
    [No Abstract]   [Full Text] [Related]  

  • 7. Thrombolytic therapy for acute myocardial infarction.
    Haley FL
    J Tenn Med Assoc; 1989 Apr; 82(4):183-6. PubMed ID: 2497271
    [No Abstract]   [Full Text] [Related]  

  • 8. Emergent decision-making: defining the patient perspective.
    Knudtson ML
    Can J Cardiol; 2005 Apr; 21(5):433-4. PubMed ID: 15861261
    [No Abstract]   [Full Text] [Related]  

  • 9. Is the use of t-PA as compared with streptokinase cost effective?
    Armentano R; Favaloro RG
    N Engl J Med; 1995 Oct; 333(15):1009-10. PubMed ID: 7666905
    [No Abstract]   [Full Text] [Related]  

  • 10. Is the use of t-PA as compared with streptokinase cost effective?
    Rose EA
    N Engl J Med; 1995 Oct; 333(15):1009; author reply 1010. PubMed ID: 7666904
    [No Abstract]   [Full Text] [Related]  

  • 11. Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.
    Boland A; Dundar Y; Bagust A; Haycox A; Hill R; Mujica Mota R; Walley T; Dickson R
    Health Technol Assess; 2003; 7(15):1-136. PubMed ID: 12773258
    [No Abstract]   [Full Text] [Related]  

  • 12. Thrombolytic therapy for acute myocardial infarction: GUSTO criticized.
    Friedman HS
    N Engl J Med; 1994 Feb; 330(7):504; author reply 505-6. PubMed ID: 8289861
    [No Abstract]   [Full Text] [Related]  

  • 13. [Thrombolytic therapy in acute myocardial infarction].
    Pedersen TR
    Tidsskr Nor Laegeforen; 1994 May; 114(14):1646-7. PubMed ID: 8079271
    [No Abstract]   [Full Text] [Related]  

  • 14. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
    Lorenzoni R; Fattore G; Gensini G
    G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tissue plasminogen activator is the best thrombolytic agent].
    Bates E
    Arq Bras Cardiol; 1994 Jul; 63(1):57-8. PubMed ID: 7857215
    [No Abstract]   [Full Text] [Related]  

  • 16. [Are the publicized advantages of thrombolytic treatment of myocardial infarct with recombinant t-PA (ACTILYSE) in comparison with streptokinase so decisive, that despite the high cost a general use of ACTILYSE is justified?].
    Gulba DC
    Internist (Berl); 1992 May; 33(5):364-5. PubMed ID: 1612871
    [No Abstract]   [Full Text] [Related]  

  • 17. [Thrombolytic therapy of acute myocardial infarction].
    Chen JL
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(1):69-70. PubMed ID: 15808085
    [No Abstract]   [Full Text] [Related]  

  • 18. Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy.
    Califf RM; Stump D; Topol EJ; Mark DB
    Am Heart J; 1999 May; 137(5):S90-3. PubMed ID: 10220606
    [No Abstract]   [Full Text] [Related]  

  • 19. Early patency in acute myocardial infarction.
    Belenkie I
    Can J Cardiol; 1993 Mar; 9(2):149-51. PubMed ID: 8490781
    [No Abstract]   [Full Text] [Related]  

  • 20. Thrombolytic therapy of myocardial infarction--it's time for science, not marketing: the perspective of a practicing cardiologist.
    Vogel JH
    Clin Cardiol; 1991 Jul; 14(7):548. PubMed ID: 1810292
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.